Pancreatic CancerNCT07177599
Pancreatic Disease Burden in Older Adults (1990-2040)
An observational study of Pancreatic Cancer and Pancreatitis, run by Changhai Hospital.
Trial summary
Using data from the Global Burden of Disease Study 2021, the investigators analyzed age-standardized incidence, mortality, and disability-adjusted life-years (DALYs) for pancreatic cancer and pancreatitis in adults aged ≥70 years across 204 countries and territories, stratified by sex, Socio-Demographic Index (SDI)… Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Pancreatic Cancer, Pancreatitis
- What is being tested?
- Natural history
- How many people
- 723,415 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 1990to 11 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: The study population consisted of patients aged 70 years or older who were diagnosed with either pancreatic cancer or pancreatitis between 1990 and 2021. Individuals under the age of 70 were excluded from participation. Additionally, those with comorbid non-pancreatic diseases were also excluded to minimize potential confounding effects and to maintain a focus on conditions specifically related to the pancreas.
Who may be able to join
- Diagnosis with pancreatic cancer or pancreatitis
- Diagnosis in 1990 through 2021
- Age 70+ years
Who cannot join
- Age <70 years
- Other non-pancreatic diseases
About this study
Official title: Global, Regional, and National Burdens of Pancreatic Cancer and Pancreatitis Among Older Adults From 1990 to 2021 With Projections to 2040: A Comprehensive and Comparative Investigation
Using data from the Global Burden of Disease Study 2021, the investigators analyzed age-standardized incidence, mortality, and disability-adjusted life-years (DALYs) for pancreatic cancer and pancreatitis in adults aged ≥70 years across 204 countries and territories, stratified by sex, Socio-Demographic Index (SDI), health system performance, and region. The investigators calculated estimated annual percentage changes (EAPCs), applied age-period-cohort modelling, and used Bayesian models to project future burden. Attributable burdens for key risk factors were also estimated.
- Conditions
- Pancreatic Cancer, Pancreatitis
- Being tested
- Natural history
- Medical subject headings
- Pancreatic Neoplasms, Pancreatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Natural historyBiological
Natural history of pancreatic diseases
| Study group | Role | What they receive |
|---|---|---|
| Pancreatic Cancer | Not described Receives: Biological: Natural history | |
| Pancreatitis | Not described Receives: Biological: Natural history |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence
The number of new cases of a givencause during a given period in aspecified population. It is xpressed as the number of newcases in a year divided by the mid-year population size.
Measured: 1990-2021
Deaths
Deaths occurring in a population during a certain time period.
Measured: 1990-2021
Disability-adjusted life years (DALYs)
The sum of years lost due to premature death (YLLs) and yearslived with disability (YLDs). DALYs are also defined as years of healthy life lost.
Measured: 1990-2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start1 Jan 1990
- Primary completion31 Dec 2021
- Study completion11 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Changhai HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 723,415 participants (actual)
Sponsor and investigators
- Lead sponsor
- Changhai Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Huang Hai, Changhai Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177599
- Sponsor's protocol ID
- GePCPS-01
- Status last verified
- Sep 2025
- First submitted
- 10 Sep 2025
- Last updated
- 17 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Global, Regional, and National Burdens of Pancreatic Cancer and Pancreatitis Among Older Adults From 1990 to 2021 With Projections to 2040: A Comprehensive and Comparative Investigation
- ClinicalTrials.gov ID
- NCT07177599
- Acronym / sponsor ID
- GePCPS-01
- Conditions
- Pancreatic Cancer, Pancreatitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 723,415 participants (actual)
- Lead sponsor
- Changhai HospitalUniversity, hospital or other
- Study start
- 1 Jan 1990 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 11 Sep 2025 (actual)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using data from the Global Burden of Disease Study 2021, the investigators analyzed age-standardized incidence, mortality, and disability-adjusted life-years (DALYs) for pancreatic cancer and pancreatitis in adults aged ≥70 years across 204 countries and territories, stratified by sex, Socio-Demographic Index (SDI), health system performance, and region. The investigators calculated estimated annual percentage changes (EAPCs), applied age-period-cohort modelling, and used Bayesian models to project future burden. Attributable burdens for key risk factors were also estimated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pancreatic Cancer | – | Biological: Natural history |
| Pancreatitis | – | Biological: Natural history |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The study population consisted of patients aged 70 years or older who were diagnosed with either pancreatic cancer or pancreatitis between 1990 and 2021. Individuals under the age of 70 were excluded from participation. Additionally, those with comorbid non-pancreatic diseases were also excluded to minimize potential confounding effects and to maintain a focus on conditions specifically related to the pancreas.
Key inclusion criteria (3 listed)
- Diagnosis with pancreatic cancer or pancreatitis
- Diagnosis in 1990 through 2021
- Age 70+ years
Key exclusion criteria (2 listed)
- Age <70 years
- Other non-pancreatic diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Natural historyNatural history of pancreatic diseases | Biological | Pancreatic Cancer, Pancreatitis |
Primary outcome
Incidence
Time frame: 1990-2021
The number of new cases of a givencause during a given period in aspecified population. It is xpressed as the number of newcases in a year divided by the mid-year population size.
Deaths
Time frame: 1990-2021
Deaths occurring in a population during a certain time period.
Disability-adjusted life years (DALYs)
Time frame: 1990-2021
The sum of years lost due to premature death (YLLs) and yearslived with disability (YLDs). DALYs are also defined as years of healthy life lost.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer and Pancreatitis, run by Changhai Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence (time frame: 1990-2021). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.